MX392374B - Peptidos terapeuticos relacionados con mots-c. - Google Patents

Peptidos terapeuticos relacionados con mots-c.

Info

Publication number
MX392374B
MX392374B MX2019003567A MX2019003567A MX392374B MX 392374 B MX392374 B MX 392374B MX 2019003567 A MX2019003567 A MX 2019003567A MX 2019003567 A MX2019003567 A MX 2019003567A MX 392374 B MX392374 B MX 392374B
Authority
MX
Mexico
Prior art keywords
methods
mots
therapeutic peptides
peptides related
treating
Prior art date
Application number
MX2019003567A
Other languages
English (en)
Other versions
MX2019003567A (es
Inventor
Kenneth C Cundy
Kent K Grindstaff
Liang Zeng Yan
Remi Magnan
Wendy Luo
Yongjin Yao
Original Assignee
Cohbar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cohbar Inc filed Critical Cohbar Inc
Publication of MX2019003567A publication Critical patent/MX2019003567A/es
Publication of MX392374B publication Critical patent/MX392374B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)

Abstract

La presente invención se refiere a péptidos y análogos peptídicos y métodos para tratar una enfermedad metabólica, por ejemplo, obesidad, diabetes, métodos para tratar cáncer, métodos para tratar una enfermedad hepática, y métodos para modular el metabolismo del ácido graso.
MX2019003567A 2016-09-28 2017-09-27 Peptidos terapeuticos relacionados con mots-c. MX392374B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662401123P 2016-09-28 2016-09-28
PCT/US2017/053597 WO2018064098A1 (en) 2016-09-28 2017-09-27 Therapeutic mots-c related peptides

Publications (2)

Publication Number Publication Date
MX2019003567A MX2019003567A (es) 2019-12-02
MX392374B true MX392374B (es) 2025-03-24

Family

ID=60164788

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003567A MX392374B (es) 2016-09-28 2017-09-27 Peptidos terapeuticos relacionados con mots-c.

Country Status (11)

Country Link
US (3) US11111271B2 (es)
EP (1) EP3519431A1 (es)
JP (1) JP7035033B2 (es)
KR (1) KR20190057110A (es)
CN (1) CN110072883A (es)
AU (1) AU2017336440B2 (es)
CA (1) CA3038292A1 (es)
IL (1) IL265463A (es)
MX (1) MX392374B (es)
TW (1) TW201819398A (es)
WO (1) WO2018064098A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018064098A1 (en) * 2016-09-28 2018-04-05 Cohbar, Inc. Therapeutic mots-c related peptides
JP2021519321A (ja) * 2018-03-27 2021-08-10 コーバー、インコーポレイテッド ペプチド含有製剤
AU2018426503A1 (en) * 2018-06-07 2021-01-21 Hanyi Bio-Technology Company Ltd. Pharmaceutical composition for preventing diabetes and use thereof
KR20210121132A (ko) * 2019-01-28 2021-10-07 코바, 인크. 치료용 펩티드
CN110818804B (zh) * 2019-10-21 2021-06-04 兰州大学 脑靶向肽及其在制备增强记忆药物中的应用
CN115867648A (zh) * 2020-02-14 2023-03-28 西北大学 将用于遗传密码重编程的化学底物扩展至包括长链碳和环状氨基酸
IL303813A (en) 2020-12-21 2023-08-01 Univ Cornell Peptide-linked drug delivery system
CN113440599A (zh) * 2021-08-11 2021-09-28 南京市妇幼保健院 MOTS-c肽及其衍生物在制备妊娠期糖尿病治疗药物中的应用
CN113876929B (zh) * 2021-11-22 2024-02-23 中国人民解放军陆军军医大学 肽MOTS-c在制备治疗帕金森药物中的应用
CN115444926A (zh) * 2022-05-10 2022-12-09 江南大学 MOTS-c肽及其衍生物在制备放射性肺损伤治疗药物中的应用
WO2023249904A1 (en) * 2022-06-20 2023-12-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating diabetes
US12064467B2 (en) * 2022-10-28 2024-08-20 Transdermal Biotechnology, Inc. Systems and methods for delivery of humanin or other peptides
KR102741555B1 (ko) * 2024-04-30 2024-12-13 주식회사 미토스테라퓨틱스 피부 투과도가 높은 미토콘드리아 유래 펩타이드를 포함하는 피부 주름 개선 또는 미백용 조성물
CN119241659B (zh) * 2024-10-08 2025-09-19 西北大学 MOTS-c及其氨基酸突变多肽在伤口愈合方面的用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US5846528A (en) 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US6015709A (en) 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
WO2001076532A2 (en) 2000-04-11 2001-10-18 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
AU6808001A (en) 2000-05-23 2001-12-03 Neurologix Inc Glutamic acid decarboxylase (gad) based delivery systems
US7588757B2 (en) 2001-03-14 2009-09-15 Genzyme Corporation Methods of treating Parkinson's disease using recombinant adeno-associated virus virions
PT2573170T (pt) 2001-12-17 2018-03-26 Univ Pennsylvania Sequências de um vírus adenoassociado (aav) de serotipo 9, vetor contendo as mesmas, e suas utilizações
AU2003274397A1 (en) 2002-06-05 2003-12-22 University Of Florida Production of pseudotyped recombinant aav virions
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20040258666A1 (en) 2003-05-01 2004-12-23 Passini Marco A. Gene therapy for neurometabolic disorders
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2006119432A2 (en) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
EP1857552A1 (en) 2006-05-20 2007-11-21 Cargill Incorporated Thermostable xylose isomerase enzyme
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
EP1986661B1 (en) 2006-02-08 2018-08-29 Genzyme Corporation Gene therapy for niemann-pick disease type a
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
US8292769B2 (en) 2006-11-22 2012-10-23 Lawson Jr Thomas Towles Transmission
US8309525B2 (en) 2007-05-30 2012-11-13 Albert Einstein College Of Medicine Of Yeshiva University Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof
CA2692392A1 (en) * 2007-06-29 2009-01-08 Centocor Ortho Biotech Inc. Anti- mcp-1 antibodies, compositions, methods and uses
CN103298935A (zh) 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
US7998928B2 (en) 2007-09-14 2011-08-16 The Regents Of The University Of California Method of treatment of type-1 diabetes with a humanin analogue
TWI541020B (zh) 2008-04-17 2016-07-11 巴克斯歐塔公司 生物活性胜肽
US8637470B2 (en) 2008-05-01 2014-01-28 The Regents Of The University Of California Small humanin-like peptides
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
AU2009327418A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
SG10201908848RA (en) 2010-03-29 2019-10-30 Univ Pennsylvania Pharmacologically induced transgene ablation system
DK2826860T3 (en) 2010-04-23 2018-12-03 Univ Massachusetts CNS targeting AAV vectors and methods for their use
WO2012009709A1 (en) * 2010-07-16 2012-01-19 Sudhir Paul Hiv cd4 binding site based covalent immunogen compositions
EP2634253B1 (en) 2010-10-27 2016-05-11 Jichi Medical University Adeno-associated virus virions for transferring genes into neural cells
JP6091435B2 (ja) 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達
US20130123168A1 (en) 2011-06-17 2013-05-16 The Regents Of The University Of California Humanin and humanin-analogues for the management of atherosclerosis
EP2986314A4 (en) 2013-03-15 2016-04-13 Univ Indiana Res & Tech Corp PRODRUGS WITH EXTENDED EFFECT
BR112015023500B1 (pt) * 2013-03-15 2021-01-12 The Regents Of The University Of California composição farmacêutica
CA2912678C (en) 2013-05-15 2023-10-10 Regents Of The University Of Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
WO2015168666A2 (en) 2014-05-02 2015-11-05 Genzyme Corporation Aav vectors for retinal and cns gene therapy
CN112553229A (zh) 2014-11-05 2021-03-26 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
MA41451A (fr) 2015-02-04 2017-12-12 Univ Washington Constructions anti-tau
WO2018064098A1 (en) 2016-09-28 2018-04-05 Cohbar, Inc. Therapeutic mots-c related peptides

Also Published As

Publication number Publication date
AU2017336440B2 (en) 2022-06-02
US11753445B2 (en) 2023-09-12
US11111271B2 (en) 2021-09-07
JP2020501514A (ja) 2020-01-23
US20200181197A1 (en) 2020-06-11
WO2018064098A1 (en) 2018-04-05
TW201819398A (zh) 2018-06-01
US20220242912A1 (en) 2022-08-04
US20210363187A1 (en) 2021-11-25
CA3038292A1 (en) 2018-04-05
EP3519431A1 (en) 2019-08-07
MX2019003567A (es) 2019-12-02
JP7035033B2 (ja) 2022-03-14
CN110072883A (zh) 2019-07-30
US11332497B2 (en) 2022-05-17
IL265463A (en) 2019-05-30
AU2017336440A1 (en) 2019-04-11
KR20190057110A (ko) 2019-05-27

Similar Documents

Publication Publication Date Title
MX392374B (es) Peptidos terapeuticos relacionados con mots-c.
CO2018012482A2 (es) Formulaciones de un inhibidor de lsd1
PE20180523A1 (es) Compuestos co-agonistas del glucacon y peptido-1 similar al glugacon (glp-1)
UY35548A (es) Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
MX2015012034A (es) El péptido mots3 derivado de mitocondrias regula el metabolismo y supervivencia celular.
MX2021005187A (es) Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3.
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
BR112019012062A2 (pt) tratamento de uma doença do trato gastrointestinal com um inibidor de jak e dispositivos
MX2018015853A (es) Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
GT201500051A (es) Inhibidores de glucosilceramida sintasa
MX2017013801A (es) Métodos para tratar el cáncer.
MX365458B (es) Agonistas de glucagon/peptido similiar al glucagon de tipo 1 (glp-1) para el tratamiento de la obesidad.
CL2020001495A1 (es) Composiciones y método para el tratamiento de enfermedades metabólicas
CO2018003224A2 (es) Formulaciones de aminoacidos de liberacion modificada administradas oralmente
MX2016001587A (es) Inhibidores de kdm1a para el tratamiento de enfermedades.
MX2017016253A (es) Anticuerpos para cd40.
BR112017012381A2 (pt) imunoterapia para doença angiogênica
BR112018010155A2 (pt) segmentação do receptor formil-peptídeo 2/receptor lipoxina a4 (fpr2/alx) para tratamento de doença cardíaca
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
MX2018006613A (es) Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
DOP2017000123A (es) Análogos de urea unidos sustituidos como moduladores de sirtuina
MX2018013221A (es) Compuestos de pirazol disustituidos para el tratamiento de enfermedades.
CO2017005566A2 (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
CL2016001786A1 (es) Regulación del metabolismo de ornitina para manipular el contenido de glicoformas ricas en manosa de proteínas recombinantes.
CR20180080A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas